Famotidine does not decrease risk for mortality in COVID-19

Results from a recent study did not demonstrate a correlation between in-hospital famotidine use and a reduced risk for mortality in COVID-19 patients.“Until safety and efficacy of these drugs are established by randomized controlled trials, results from these observational studies should be interpreted with caution,” Samrat Yeramaneni, MBBS, PhD, from the Sarah Cannon Research Institute, HCA Healthcare in Nashville, and colleagues wrote.Yeramaneni and colleagues identified 7,158 patients who tested positive for SARS-CoV-2. Thirty-day all-cause mortality served as the primaryRead More

Share on facebook
Share on twitter
Share on linkedin